Two alleles of the human paraoxonase gene produce different amounts of mRNA: An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 11, 1997, Pages 2935-2939

  Leviev, Ilia ^a   Negro, Franco ^a   James, Richard W ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Atherosclerosis; HDL; LDL; Oxidative stress

Indexed keywords

COMPLEMENTARY DNA; LEUCINE; LIVER ENZYME; MESSENGER RNA; METHIONINE;

ARTICLE; ATHEROSCLEROSIS; ENZYME BLOOD LEVEL; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; LIVER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING;

EID: 0031443643     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.11.2935     Document Type: Article

References (22)

1. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979;76:333-337.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein cholesterol that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
3. Tribble DL. Lipoprotein oxidation in dyslipidemia: insights into general mechanisms affecting lipoprotein oxidative behaviour. Curr Opin Lipidol. 1995;6:196-208.
4. Mackness MI, Hallam SD, Peard T, Warner S, Walker CH. The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol. 1985;82:675-677.
5. Blatter M-C, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem. 1993;211:871-879.
6. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286:152-154.
7. Mackness MI, Arrol S, Abbot C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
8. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
9. Ruiz J, Blanché H, James RW, et al. The polymorphism (Gln-Arg192) of the high-density lipoprotein-bound enzyme paraoxonase is an independent cardiovascular risk factor in non-insulin dependent diabetic patients. Lancet. 1995;346:869-872.
10. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease. J Clin Invest. 1995;96:3005-3008.
11. Antikainen M, Murtomaki S, Syvänne M, et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with risk of coronary artery disease in Finns. J Clin Invest. 1996;98:883-885.
12. Herrmann S-M, Blanc H, Poirier O, et al. The Gin/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. 1996;126:299-304.
13. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press; 1992:51-91.
14. Davis HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. 1996;14:334-336.
15. Blatter Garin M-C, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997;99:62-66.
16. Mackness MI, Walker CH, Carlson LA. Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem. 1987;33:587-588.
17. James RW, Blatter Garin M-C, von Eckardstein A, Calabresi L, Assman G, Franceschini G. Modulated activity and concentration of paraoxonase in AIMilano patients compared to other HDL deficiencies. Circulation. 1996;94:I-222. Abstract.
18. Blatter Garin M-C, Abbot C, Messmer S, et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994;304:549-554.
19. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
20. Hassett C, Richter RJ, RH, et al. Characterisation of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 1991;30:10141-10149.
21. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
22. Shin DM, Gu L, Hama S, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 1996;97:1630-1639.